Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
PDPDS Biotechnology Corporation logo

PDS Biotechnology Corporation (PDSB)

NASDAQ Capital Market · Currency in USD
$1.11 ▼ -0.05 (-4.31%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.11 ▲ +0.00 (+0.21%)
After hours: Oct 23, 7:57 PM ET

Summary

Previous Close
$1.16
Open
$1.11
Day's Range
$1.06 – $1.13
52 Week Range
$0.20 – $1.79
Volume
2,699,071
Avg. Volume
17,563,127
Market Cap
$61.96M
Beta (5Y Monthly)
1.45
PE Ratio (TTM)
--
EPS (TTM)
-$0.60
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$9.00

Profile: PDS Biotechnology Corporation

Sector
Healthcare
Industry
Biotechnology
Full-time employees
21
CEO
Frank K. Bedu-Addo

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.11
DateEst.Actual
Aug 13, 2026-$0.13-$0.18Miss
May 13, 2026-$0.15-$0.13Beat
Mar 30, 2026-$0.20-$0.14Beat
Nov 13, 2025-$0.21-$0.19Beat
Aug 13, 2025-$0.24-$0.21Beat
May 14, 2025-$0.25-$0.21Beat

Analyst view

Consensus price target
$9.00 ▲ +710.8%
Range $9.00 – $9.00
Rating: Buy
Buy 86% · Hold 14% · Sell 0%

Get free alerts on PDSB and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.